SNOASonoma Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Sonoma Pharmaceuticals, Inc. against Surgical & Medical Instruments & Apparatus — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNOA본 종목 | $6M#7 | — | 0.9x#7 | 0.3x#3 | 36.7%#3 | -8.2%#9 | -12.6%#2 | 0.0%#1 | -174.4%#4 | — | -70.3%#4 | — |
| SINT | $11M#1 | — | 2.3x#9 | 10.9x#12 | -64.7%#10 | 6.0%#6 | -1053.1%#9 | -214.6%#6 | -852.2%#8 | 3#4 | -57.9%#3 | — |
| ADGM | $10M#2 | — | — | — | — | — | — | — | -131.2%#3 | — | -72.1%#6 | — |
| ALUR | $10M#3 | — | — | 0.7x#5 | -52.6%#9 | -299.5%#15 | -198.0%#5 | — | — | 2#5 | -97.9%#15 | — |
| BTCY | $10M#4 | — | — | 0.6x#4 | 16.0%#7 | 71.5%#1 | 10.6%#1 | — | — | — | -31.2%#1 | — |
| BEATW | $7M#5 | — | 0.9x#6 | — | — | -8.1%#8 | — | -257.0%#8 | — | — | -41.1%#2 | — |
| PFSA | $962979#16 | 0.0x#1 | — | 9.6x#11 | — | -288.1%#14 | -27706.0%#13 | — | — | — | -99.9%#16 | — |
| NVNO | $6M#6 | — | 0.3x#2 | 198.0x#14 | -83.3%#11 | 10.8%#3 | -66891.8%#14 | -94.2%#4 | — | — | -71.3%#5 | — |
| CODX | $6M#9 | — | 0.5x#4 | 9.5x#10 | -84.1%#12 | -23.7%#11 | -8058.8%#12 | -369.7%#9 | -389.5%#5 | — | -92.5%#12 | — |
| INBS | $6M#8 | — | 1.1x#8 | 1.4x#8 | 38.1%#2 | -17.6%#10 | -299.1%#6 | -225.6%#7 | -397.9%#6 | — | -85.9%#8 | — |
| OSRH | $4M#10 | 0.6x#3 | — | 1.4x#7 | -17.7%#8 | -162.0%#13 | -631.0%#8 | — | — | 2#5 | -84.0%#7 | — |
| BJDX | $4M#11 | — | 0.4x#3 | 14.6x#13 | — | 11.3%#2 | -2791.9%#11 | -72.7%#3 | — | — | -86.6%#9 | — |
| TNON | $3M#13 | 0.3x#2 | — | 0.7x#6 | 20.4%#5 | 8.2%#5 | -324.3%#7 | — | — | — | -89.7%#10 | — |
| VVOS | $4M#12 | — | — | 0.2x#1 | 16.0%#6 | -90.1%#12 | -114.1%#4 | — | -780.5%#7 | 4#2 | -94.9%#14 | — |
| NXGL | $2M#14 | — | 0.5x#5 | 0.2x#2 | 31.5%#4 | 8.6%#4 | -29.3%#3 | -60.6%#2 | -68.1%#1 | 4#2 | -90.2%#11 | — |
| VTAK | $2M#15 | — | 0.1x#1 | 2.8x#9 | 95.0%#1 | -3.2%#7 | -2581.6%#10 | -97.8%#5 | -79.7%#2 | 5#1 | -94.1%#13 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3841). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice